KRAS Inhibition Using MRTX1257: a Novel Radio-sensitizing Partner

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2023 Nov 1

PMID 37907934

Authors

Pierre-Antoine Laurent

Marina Milic

Clement Quevrin

Lydia Meziani

Winchygn Liu

Daphne Morel

Nicolas Signolle

Celine Clemenson

Antonin Levy

Michele Mondini

Eric Deutsch

Affiliations

Soon will be listed here.

Abstract

Background: KRAS activating mutations are considered the most frequent oncogenic drivers and are correlated with radio-resistance in multiple cancers including non-small cell lung cancer (NSCLC) and colorectal cancer. Although KRAS was considered undruggable until recently, several KRAS inhibitors have recently reached clinical development. Among them, MRTX849 (Mirati Therapeutics) showed encouraging clinical outcomes for the treatment of selected patients with KRAS mutated NSCLC and colorectal cancers. In this work, we explore the ability of MRTX1257, a KRAS inhibitor analogous to MRTX849, to radio-sensitize KRAS mutated cell lines and tumors.

Methods: Both in vitro and in vivo models of radiotherapy (RT) in association with MRTX1257 were used, with different RAS mutational profiles. We assessed in vitro the radio-sensitizing effect of MRTX1257 in CT26 KRAS, CT26 WT, LL2 WT and LL2 NRAS KO (LL2 NRAS) cell lines. In vivo, we used syngeneic models of subcutaneous CT26 KRAS tumors in BALB/c mice and T cell deficient athymic nu/nu mice to assess both the radio-sensitizing effect of MRTX1257 and its immunological features.

Results: MRTX1257 was able to radio-sensitize CT26 KRAS cells in vitro in a time and dose dependent manner. Moreover, RT in association with MRTX1257 in BALB/c mice bearing CT26 KRAS subcutaneous tumors resulted in an observable cure rate of 20%. However, no durable response was observed with similar treatment in athymic nude mice. The analysis of the immune microenvironment of CT26 KRAS tumors following RT and MRTX1257 showed an increase in the proportion of various cell subtypes including conventional CD4 + T cells, dendritic cells type 2 (cDC2) and inflammatory monocytes. Furthermore, the expression of PD-L1 was dramatically down-regulated within both tumor and myeloid cells, thus illustrating the polarization of the tumor microenvironment towards a pro-inflammatory and anti-tumor phenotype following the combined treatment.

Conclusion: This work is the first to demonstrate in vitro as in vivo the radio-sensitizing effect of MRTX1257, a potent KRAS inhibitor compatible with oral administration, in CT26 KRAS mutated cell lines and tumors. This is a first step towards the use of new combinatorial strategies using KRAS inhibitors and RT in KRAS mutated tumors, which are the most represented in NSCLC with 14% of patients harboring this mutational profile.

References

Strauss L, Mahmoud M, Weaver J, Tijaro-Ovalle N, Christofides A, Wang Q . Targeted deletion of PD-1 in myeloid cells induces antitumor immunity. Sci Immunol. 2020; 5(43). PMC: 7183328. DOI: 10.1126/sciimmunol.aay1863. View

Castle J, Loewer M, Boegel S, de Graaf J, Bender C, Tadmor A . Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics. 2014; 15:190. PMC: 4007559. DOI: 10.1186/1471-2164-15-190. View

Janne P, Riely G, Gadgeel S, Heist R, Ou S, Pacheco J . Adagrasib in Non-Small-Cell Lung Cancer Harboring a Mutation. N Engl J Med. 2022; 387(2):120-131. DOI: 10.1056/NEJMoa2204619. View

Liao W, Overman M, Boutin A, Shang X, Zhao D, Dey P . KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell. 2019; 35(4):559-572.e7. PMC: 6467776. DOI: 10.1016/j.ccell.2019.02.008. View

Barton M, Jacob S, Shafiq J, Wong K, Thompson S, Hanna T . Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012. Radiother Oncol. 2014; 112(1):140-4. DOI: 10.1016/j.radonc.2014.03.024. View

Buday L, Downward J . Many faces of Ras activation. Biochim Biophys Acta. 2008; 1786(2):178-87. DOI: 10.1016/j.bbcan.2008.05.001. View

Sklar M . The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science. 1988; 239(4840):645-7. DOI: 10.1126/science.3277276. View

Ostrem J, Peters U, Sos M, Wells J, Shokat K . K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013; 503(7477):548-51. PMC: 4274051. DOI: 10.1038/nature12796. View

Rait A, Pirollo K, Will D, Peyman A, Rait V, Uhlmann E . 3'-End conjugates of minimally phosphorothioate-protected oligonucleotides with 1-O-hexadecylglycerol: synthesis and anti-ras activity in radiation-resistant cells. Bioconjug Chem. 2000; 11(2):153-60. DOI: 10.1021/bc990106n. View

10.

Williams T, Flecha A, Keller P, Ram A, Karnak D, Galban S . Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer. Mol Cancer Ther. 2012; 11(5):1193-202. PMC: 3349776. DOI: 10.1158/1535-7163.MCT-12-0098. View

11.

Slebos R, Kibbelaar R, Dalesio O, Kooistra A, Stam J, Meijer C . K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med. 1990; 323(9):561-5. DOI: 10.1056/NEJM199008303230902. View

12.

Lito P, Solomon M, Li L, Hansen R, Rosen N . Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science. 2016; 351(6273):604-8. PMC: 4955282. DOI: 10.1126/science.aad6204. View

13.

Canon J, Rex K, Saiki A, Mohr C, Cooke K, Bagal D . The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019; 575(7781):217-223. DOI: 10.1038/s41586-019-1694-1. View

14.

Bankhead P, Loughrey M, Fernandez J, Dombrowski Y, McArt D, Dunne P . QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017; 7(1):16878. PMC: 5715110. DOI: 10.1038/s41598-017-17204-5. View

15.

Zheng Y, Liu Y, Zhang F, Su C, Chen X, Zhang M . Radiation combined with KRAS-MEK inhibitors enhances anticancer immunity in KRAS-mutated tumor models. Transl Res. 2022; 252:79-90. DOI: 10.1016/j.trsl.2022.08.005. View

16.

Jones R, Sutton P, Evans J, Clifford R, McAvoy A, Lewis J . Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. Br J Cancer. 2017; 116(7):923-929. PMC: 5379149. DOI: 10.1038/bjc.2017.37. View

17.

Liu P, Wang Y, Li X . Targeting the untargetable KRAS in cancer therapy. Acta Pharm Sin B. 2019; 9(5):871-879. PMC: 6804475. DOI: 10.1016/j.apsb.2019.03.002. View

18.

Fiala O, Buchler T, Mohelnikova-Duchonova B, Melichar B, Matejka V, Holubec L . G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. Tumour Biol. 2015; 37(5):6823-30. DOI: 10.1007/s13277-015-4523-7. View

19.

Bernhard E, McKenna W, Hamilton A, Sebti S, Qian Y, Wu J . Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res. 1998; 58(8):1754-61. View

20.

Allam A, Taghian A, Gioioso D, Duffy M, Suit H . Intratumoral heterogeneity of malignant gliomas measured in vitro. Int J Radiat Oncol Biol Phys. 1993; 27(2):303-8. DOI: 10.1016/0360-3016(93)90241-m. View